PanC (No. 47) | CS (No. 51) | |
---|---|---|
Pathogenic-likely pathogenic | ||
ATM* | 1 (2.1%) | 0 |
BRCA2* | 4 (8.5%) | 0 |
CFTR* | 5 (10.6%) | 1 (2.0%) |
CHEK2 | 1 (2.1%) | 0 |
MUTYH | 0 | 1 (2.0%) |
No. of variants | 10 | 2 |
No. of individuals with variant(s) | 8 | 2 |
Pathogenic-likely pathogenic/VUS | ||
ATM | 0 | 1 (2.0%) |
CFTR* | 3 (6.4%) | 5 (9.8%) |
No. of variants | 3 | 5 |
No. of individuals with variant(s) | 3 | 6 |
VUS | ||
APC* | 1 (2.1%) | 4 (7.8%) |
ATM* | 2 (4.3%) | 5 (9.8%) |
BRCA1* | 0 | 2 (3.9%) |
CDKN2A | 1 (2.1%) | 0 |
CFTR* | 3 (6.4%) | 5 (9.8%) |
CHEK2* | 1 (2.1%) | 1 (2.0%) |
ERBB2 | 1 (2.1%) | 0 |
FANCC* | 0 | 2 (3.9%) |
FANCG | 0 | 1 (2.0%) |
MLH1 | 0 | 1 (2.0%) |
MSH3 | 1 (2.1%) | 0 |
MSH6 | 1 (2.1%) | 0 |
MUTYH* | 1 (2.1%) | 3 (5.9%) |
PMS2* | 0 | 1 (2.0%) |
POLD1* | 2 (4.3%) | 0 |
POLE | 1 (2.1%) | 2 (3.9%) |
TP53 | 1 (2.1%) | 0 |
No. of variants | 15 | 31 |
No. of individuals with variant(s) | 15 | 25 |
Undefined | ||
ERBB2 | 0 | 3 (5.9%) |
MSH3 | 0 | 1 (2.1%) |
ATM | 0 | 1 (2.1%) |
CFTR | 0 | 1 (2.1%) |
FANCC | 1 (2.1%) | 0 |
CHEK2 | 1 (2.1%) | 0 |
POLD1 | 1 (2.1%) | 0 |
RNF43 | 0 | 1 (2.1%) |
No. of variants | 3 | 7 |
No. of individuals with variant(s) | 3 | 7 |